This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
British Broadcasting Corporation, London (2006) Drug 'may reverse liver disease'. [http://news.bbc.co.uk/2/hi/health/5382172.stm] (accessed 22 March 2007)
Bonis PA et al. (2001) Is liver fibrosis reversible? N Engl J Med 344: 452–454
Nagula S et al. (2006) Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol 44: 111–117
Issa R et al. (2004) Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126: 1795–1808
Herold C et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 21: 260–265
Ratziu V et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898–1906
Gawrieh S et al. (2005) Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 11: 1207–1213
Foucher J et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403–408
Ngo Y et al. (2006) A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 52: 1887–1896
Huang H et al. (2006) Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130: 1679–1687
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has declared associations with the following companies/organizations: Angion Biomedica, Intercept, Conatus, XTL, Stromedix, Breath ID, Biogen Idec, Genzyme, Gilead, Glaxo Smith Kline, Novartis and Pro-Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Friedman, S. Reversibility of hepatic fibrosis and cirrhosis—is it all hype?. Nat Rev Gastroenterol Hepatol 4, 236–237 (2007). https://doi.org/10.1038/ncpgasthep0813
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0813
This article is cited by
-
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Journal of Translational Medicine (2012)
-
Fuzheng Huayu Capsule (扶正化瘀胶囊) in the treatment of liver fibrosis: Clinical evidence and mechanism of action
Chinese Journal of Integrative Medicine (2012)
-
Evolving challenges in hepatic fibrosis
Nature Reviews Gastroenterology & Hepatology (2010)
-
Chinese medicines as a resource for liver fibrosis treatment
Chinese Medicine (2009)